Pfizer  1Q Revenues: $14.9 billion (-20%) 1Q Earnings: $3.1 billion (-44%) Comments: Global biopharmaceutical sales were $14.6 billion in the quarter, down 20%. Decline in Comirnaty and Paxlovid revenues drove 19% operational decrease in revenues. Comirnaty sales were $354 million, down 88% and Paxlovid sales were $2.0 billion down 50%. Global revenues from legacy Seagen, which was acquired in December of 2023, were $742 million. Vyndaqel family sales were $1.1 billion, up 66%. Eliquis sales ...